HighTide Therapeutics Inc
2511.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.74B
Close$
$0.26
91.7% downside
Current Fair Value
91.7% downsideOvervalued by 91.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.74 Billion |
|---|---|
| Enterprise Value | $1.63 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.51 |
| Beta | -0.27 |
| Outstanding Shares | 508,714,904 |
Return
| Return on Equity | -336.61% |
|---|---|
| Return on Assets | -148.54% |
| Return on Invested Capital | -188.25% |
Valuation & Multiples
| P/E Ratio | -5.4 |
|---|---|
| PEG | -25.04 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.25 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.93 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 26, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About HighTide Therapeutics Inc
51 employees
CEO: Liping Liu HighTide Therapeutics, Inc. operates as an investment holding company focused on the entire lifecycle from discovery to commercialization of innovative, multi-faceted therapeutic solutions. These solutions are specifically engineered to ...